---
# For vignette -----------------------------------------------------------------
title: "Derive: MuSyC Model -- Synergy Analysis"
description: Derive the functional form, parameterization, and implementation
  for the MuSyC synergy model.
# Document ---------------------------------------------------------------------
output: rmarkdown::html_vignette
bibliography: references.bib
editor: visual
header-includes: |
  \usepackage{chemarr}
vignette: >
  %\VignetteIndexEntry{Derive: MuSyC Model -- Synergy Analysis}
  %\VignetteKeyword{BayesPharma}
  %\VignetteEngine{knitr::rmarkdown}
  %\VignetteEncoding{UTF-8}
---




```
## Error in library(tidyverse): there is no package called 'tidyverse'
```




### MuSyC synergy model {#sec-MuSyC}
When two different treatments are combined they may interact. For end-point
assays, if the response is stronger or weaker than what would be expected with
an additive model, the treatments are said to be epistatic. For sigmoidal
dose-response models, however, the analysis may be more complicated. One drug
may not only may shift the maximal response (efficacy) of the other, but it may
also shift the effective dose and shape of the response (potency). Historically
a range of models have been proposed that capture different aspects of synergy,
for example the Bliss independence[@Bliss1956-hf] and Loewe
additivity[@Loewe1926-sr] are null-models for no synergistic efficacy or
potency, respectively. The `SynergyFinder` R package[@Ianevski2022-cb] and the
`synergy` python package[@Wooten2021-cr] can be used to visualize treatment
interactions, compute a range of synergy scores, and test if the interactions
are significant.

Recently Meyer et al.[@Meyer2019-zr,Wooten2021-lg] derived an integrated
functional synergistic sigmoidal dose-response, which has the Loewe and Bliss
models as special cases. They implemented a Bayesian model-fitting strategy in
`Matlab`, and a maximum likelihood model-fitting into the synergy python
package. To make the model more accessible to the pharmacology community, in
this section, we briefly review the `MuSyC` functional form, describe a Bayesian
implementation in `Stan`/`BRMS`, and illustrate using the model to re-analyze
how drugs and voltage may interact to modulate the current through a potassium
channel.

**MuSyC Functional Form**: The functional form for the MuSyC model gives an
equation for the response $\color{brown}{E_d}$ at doses of $\color{teal}{d_1}$
and $\color{teal}{d_2}$ of the two treatments and has $9$ free parameters
$\color{purple}{C_1}$, $\color{purple}{C_2}$, $\color{brown}{E_0}$,
$\color{brown}{E_1}$, $\color{brown}{E_2}$, $\color{brown}{E_3}$,
$\color{purple}{h_1}$, $\color{purple}{h_2}$, $\color{purple}{\alpha}$:

\begin{align}
\color{brown}{E_d} &= \frac{
          {\color{purple}{C_1}}^{\color{purple}{h_1}}{\color{purple}{C_2}}^{\color{purple}{h_2}}{\color{brown}{E_0}} +
          {\color{teal}{d_1}}^{\color{purple}{h_1}}{\color{purple}{C_2}}^{\color{purple}{h_2}}{\color{brown}{E_1}} +
          {\color{purple}{C_1}}^{\color{purple}{h_1}}{\color{teal}{d_2}}^{\color{purple}{h_2}}{\color{brown}{E_2}} +
          {\color{teal}{d_1}}^{\color{purple}{h_1}}{\color{teal}{d_2}}^{\color{purple}{h_2}}{\color{purple}{\alpha}} {\color{brown}{E_3}}
       }{
          {\color{purple}{C_1}}^{\color{purple}{h_1}}{\color{purple}{C_2}}^{\color{purple}{h_2}} +
          {\color{teal}{d_1}}^{\color{purple}{h_1}}{\color{purple}{C_2}}^{\color{purple}{h_2}} +
          {\color{purple}{C_1}}^{\color{purple}{h_1}}{\color{teal}{d_2}}^{\color{purple}{h_2}} +
          {\color{teal}{d_1}}^{\color{purple}{h_1}}{\color{teal}{d_2}}^{\color{purple}{h_2}}{\color{purple}{\alpha}}}
\end{align}

To interpret these parameters if we set $\color{teal}{d_2}=0$, then 
\begin{align}
\color{brown}{E_d} &= \frac{
          {\color{purple}{C_1}}^{\color{purple}{h_1}}{\color{brown}{E_0}} +
          {\color{teal}{d_1}}^{\color{purple}{h_1}}{\color{brown}{E_1}}
       }{
          {\color{purple}{C_1}}^{\color{purple}{h_1}} +
          {\color{teal}{d_1}}^{\color{purple}{h_1}}}
\end{align}
which is the Hill equation, which we modeled above \ref{sec:hill}. If we then
additionally set $\color{teal}{d_1}=0$ then
$\color{brown}{E_d}=\color{brown}{E_0}$, in the limit as
${\color{teal}{d_1}}\rightarrow \infty$ then
${\color{brown}{E_d}}\rightarrow {\color{brown}{E_1}}$, and if
${\color{teal}{d_1}}=\color{purple}{C_1}$ then
${\color{brown}{E_d}} = ({\color{brown}{E_0}} + {\color{brown}{E_2}})/2$, which
is the half maximal response (either the $\color{brown}{\mbox{IC}_{50}}$ if
treatment $1$ is an inhibitor or $\color{brown}{\mbox{EC}_{50}}$ if treatment
$1$ is agonist). The slope at ${\color{teal}{d_1}}={\color{purple}{C_1}}$ is 
\begin{align*}
    \frac{\mathrm{d}\;\color{brown}{E_d}}{\mathrm{d}\color{teal}{d_1}}
        &= {\color{purple}{C_1}}^{v}{\color{brown}{E_0}}
              \frac{\mathrm{d}}{\mathrm{d}\color{teal}{d_1}}
                  \frac{1}{{\color{purple}{C_1}}^{\color{purple}{h_1}} + {\color{teal}{d_1}}^{\color{purple}{h_1}}} +
           {\color{brown}{E_1}}
              \frac{\mathrm{d}}{\mathrm{d}\color{teal}{d_1}}
                   \frac{{\color{teal}{d_1}}^{h_1}}{{\color{purple}{C_1}}^{\color{purple}{h_1}} + {\color{teal}{d_1}}^{\color{purple}{h_1}}}\\
        &= {\color{purple}{C_1}}^{h_1}{\color{brown}{E_0}}
              \frac{                          h_1{\color{teal}{d_1}}^{{\color{purple}{h_1}}-1}}{\left({\color{purple}{C_1}}^{\color{purple}{h_1}} + {\color{teal}{d_1}}^{\color{purple}{h_1}}\right)^2} +
            {\color{brown}{E_1}}
               \frac{{\color{purple}{C_1}}^{\color{purple}{h_1}}h_1{\color{teal}{d_1}}^{{\color{purple}{h_1}}-1}}{\left({\color{purple}{C_1}}^{\color{purple}{h_1}} + {\color{teal}{d_1}}^{\color{purple}{h_1}}\right)^2}\\
        &= ({\color{brown}{E_0}} + {\color{brown}{E_1}})
\end{align*}

The evaluation of the functional form for ${\color{brown}{E_d}}$ is numerically
unstable. To transform using the $\mbox{log\_sum\_exp}$ trick, let

\begin{align*}
\mbox{numerator\_parts} = [\\
      &{\color{purple}{h_1}}\log({\color{purple}{C_1}}) + {\color{purple}{h_2}}\log({\color{purple}{C_2}}) + \log({\color{brown}{E_0}}),\\
      &{\color{purple}{h_1}}\log({\color{teal}{d_1}}) + {\color{purple}{h_2}}\log({\color{purple}{C_2}}) + \log({\color{brown}{E_1}}),\\
      &{\color{purple}{h_1}}\log({\color{purple}{C_1}}) + {\color{purple}{h_2}}\log({\color{teal}{d_2}}) + \log({\color{brown}{E_2}}),\\
      &{\color{purple}{h_1}}\log({\color{teal}{d_1}}) + {\color{purple}{h_2}}\log({\color{teal}{d_2}}) + \log({\color{brown}{E_3}}) + \log({\color{purple}{\alpha}}) ]\\
\mbox{denominator\_parts} = [\\
      &{\color{purple}{h_1}}\log({\color{purple}{C_1}}) + {\color{purple}{h_2}}\log({\color{purple}{C_2}}),\\
      &{\color{purple}{h_1}}\log({\color{teal}{d_1}}) + {\color{purple}{h_2}}\log({\color{purple}{C_2}}),\\
      &{\color{purple}{h_1}}\log({\color{purple}{C_1}}) + {\color{purple}{h_2}}\log({\color{teal}{d_2}}),\\
      &{\color{purple}{h_1}}\log({\color{teal}{d_1}}) + {\color{purple}{h_2}}\log({\color{teal}{d_2}})]\\
\end{align*}
Then 
$$
    E_d = \mbox{exp}\!\left(\mbox{log\_sum\_exp}(\mbox{numerator\_parts}) - \mbox{log\_sum\_exp}(\mbox{denominator\_parts})\right).
$$


#### MuSyC model BayesPharma






\#' Drug Synergy \#' MuSyC Drug Synergy model \#' \#' Assume that the response metric decreases with more effective drugs \#' Let E3 be the effect at the maximum concentration of both drugs \#' \#' \#' Special cases: \#' \* dose additive model: alpha1 = alpha2 = 0 \#' \* loewe: h1 = h2 = 1 \#' \* CI: E0 = 1, E1 = E2 = E3 = 0 \#' the drug effect is equated with percent inhibition \#' \* bliss drug independence model: \#' E0 = 1, E1 = E2 = E3 = 0, alpha1 = alpha2 = 1 \#' @param d1 Dose of drug 1 \#' @param d2 Dose of drug 2 \#' \#' @param E0 effect with no drug treatment \#' \#' \# params for drug 1 by it self \#' @param s1 drug 1 hill slope \#' @param C1 drug 1 EC50 \#' @param E1 drug 1 maximum effect \#' \#' \# params for drug 2 by it self \#' @param s2 drug 2 hill slope \#' @param C2 drug 2 EC50 \#' @param E2 drug 2 maximum effect \#' \#' @param beta synergistic efficacy \#' percent increase in a drug combination's effect \#' beyond the most efficacious single drug. \#' \#' beta \> 0 =\> synergistic efficacy \#' the effect at the maximum concentration of both drugs (E3) exceeds the \#' maximum effect of either drug alone (E1 or E2) \#' \#' beta \< 0 =\> antagonistic efficacy \#' at least one or both drugs are more efficacious as \#' single agents than in combination \#' \#' @param alpha1 synergistic potency \#' how the effective dose of drug 1 \#' is altered by the presence of drug 2 \#' @param alpha2 synergistic potency \#' how the effective dose of drug 2 \#' is altered by the presence of drug 1 \#' \#' alpha \> 1 =\> synergistic potency \#' the EC50 decreases because of the addition of the other drug, \#' corresponding to an increase in potency \#' \#' 0 \<= alpha \< 1 =\> antagonistic potency \#' the EC50 of the drug increases as a result of the other drug, \#' corresponding to a decrease in potency \#' \#' alpha1 == alpha2 if detailed balance \#' @export generate_MuSyC_effects \<- function( d1, d2, E0, s1, C1, E1, s2, C2, E2, alpha, E3) { h1 \<- MuSyC_si_to_hi(s1, C1, E0, E1) h2 \<- MuSyC_si_to_hi(s2, C2, E0, E2) numerator \<- C1\^h1 \* C2\^h2 \* E0 + d1\^h1 \* C2\^h2 \* E1 + C1\^h1 \* d2\^h2 \* E2 + d1\^h1 \* d2\^h2 \* E3 \* alpha denominator \<- C1\^h1 \* C2\^h2 + d1\^h1 \* C2\^h2 + C1\^h1 \* d2\^h2 + d1\^h1 \* d2\^h2 \* alpha numerator / denominator }

\#' Create a formula for the MuSyC synergy model \#' \#' @description setup a defaulMuSyC synergy model formula to predict \#' the `E0`, `C1`, `E1`, `s1`, `C2`, `E2`, `s2`, `log10alpha`, and `E3alpha` \#' parameters. \#' \#' @param predictors Additional formula objects to specify predictors of \#' non-linear parameters. i.e. what perturbations/experimental differences \#' should be modeled separately? (Default: 1) should a random effect be taken \#' into consideration? i.e. cell number, plate number, etc. \#' @return brmsformula \#' \#' @examples \#'\dontrun{
#'   Consider observations made using 4 different drugs and the column header
#'   containing the labels for the 4 different drugs is `predictors`.
#'   
#'      `MuSyC_formula(predictors = 0 + predictors)`
#'
#'   Consider that the cell_ID was recorded and the noise from the cell_ID is to
#'   be accounted for.
#'  
#'      `MuSyC_formula(predictors = 0 + predictors + (1|cell_ID))`
#'} \#' \#' @export MuSyC_formula \<- function( predictors = 1, ...) {

```         
predictor_eq <- rlang::new_formula(
  lhs = quote(E0 + C1 + E1 + s1 + C2 + E2 + s2 + log10alpha + E3alpha),
  rhs = rlang::enexpr(predictors))

brms::brmsformula(
  response ~ (C1^h1 * C2^h2 * E0 +
      d1^h1 * C2^h2 * E1 +
      C1^h1 * d2^h2 * E2 +
      d1^h1 * d2^h2 * E3alpha
    ) / (
      C1^h1 * C2^h2 +
      d1^h1 * C2^h2 +
      C1^h1 * d2^h2 +
      d1^h1 * d2^h2 * 10^log10alpha),
  brms::nlf(d1 ~ dose1 / d1_scale_factor),
  brms::nlf(d2 ~ dose2 / d2_scale_factor),
  brms::nlf(h1 ~ s1 * (4 * C1) / (E0 + E1)),
  brms::nlf(h2 ~ s2 * (4 * C2) / (E0 + E2)),
  predictors_eq,
  nl = TRUE,
  ...)
```

}

\#' Fit the MuSyC synergy model by dose \#' \#' @param data data.frame of experimental data \#' with columns: dose1, dose2, n_positive, count, [<group_vars>] \#' @param group_vars quosures list \#' dplyr::vars(...) columns to over when fitting synergy model \#' @param C1_prior prior distribution for Ed when d1=d1_IC50, d2=0 \#' @param C2_prior prior distribution for Ed when d1=0, d2=d2_IC50 \#' @param s1_prior prior distribution for d(Ed)/d(d1) when d1=d1_IC50, d2=0 \#' @param s2_prior prior distribution for d(Ed)/d(d2) when d1=0, d2=d2_IC50 \#' @param log10alpha_prior prior distribution for alpha synergy parameter \#' @param E0_prior prior distribution for Ed when d1=0, d2=0 \#' @param E1_prior prior distribution for Ed when d1=Inf, d2=0 \#' @param E2_prior prior distribution for Ed when d1=0, d2=Inf \#' @param E3_alpha_prior prior distribution for Ed scaled by alpha when d1=Inf, \#' d2=Inf \#' @param C1_init initial sampling distribution for the C1 parameter \#' @param C2_init initial sampling distribution for the C2 parameter \#' @param s1_init initial sampling distribution for the s1 parameter \#' @param s2_init initial sampling distribution for the s2 parameter \#' @param log10alpha_init initial sampling distribution for the alpha parameter \#' @param E0_init initial sampling distribution for the E0 parameter \#' @param E1_init initial sampling distribution for the E1 parameter \#' @param E2_init initial sampling distribution for the E2 parameter \#' @param E3_alpha_init initial sampling distribution for the E3 parameter \#' @param combine combine the grouped models into a single brms model \#' @param verbose verbose output \#' \#' @param iter number of stan NUTS sampling steps \#' @param cores number of cores used for sampling \#' @param stan_model_args stan model arguments \#' @param control stan control arguments \#' \#' The \#' \#' bernoulli_inf(n_positive / count) = \#' Ed \~ MuSyC(d1, d2, C_params, E_params, s_params, alpha) \#' \#' To improve numeric stability, the d1 and d2 and C1 and C2 variables \#' are scaled to improve numeric stability: \#' \#' d1 = dose1/max(dose1) \#' d2 = dose2/max(dose2) \#' drug1_IC50 = C1 \* max(dose1) \#' drug2_IC50 = C2 \* max(dose2) \#' \#' Functional form: \#' Ed \~ ( \#' C1\^h1 \* C2\^h2 \* E0 + \#' d1\^h1 \* C2\^h2 \* E1 + \#' C1\^h1 \* d2\^h2 \* E2 + \#' d1\^h1 \* d2\^h2 \* E3 \* alpha \#' ) / ( \#' C1\^h1 \* C2\^h2 + \#' d1\^h1 \* C2\^h2 + \#' C1\^h1 \* d2\^h2 + \#' d1\^h1 \* d2\^h2 \* alpha \#' ) \#' \#' \#' \#' \#' \#' \############################################## \#' \# Proof of the definitions of the parameters \# \#' \############################################## \#' \#' Claim: When d1=0 and d2=0 then Ed = E0 \#' Ed = (C1\^h1 \* C2\^h2 \* E0) / (C1\^h1 \* C2\^h2) \#' = E0 \#' \#' Claim: When d1=0 and d2 -\> Inf then Ed = E2 \#' Ed = (C2\^h2 \* E0 + d2\^h2 \* E2) / (C2\^h2 + d2\^h2) \#' = (d2\^h2 \* E2) / (d2\^h2) \#' = E2 \#' #; Claim: When d1=0 and d2=C2 then Ed = (E0 + E2) / 2 \#' When d1\>0 and d2 -\> Inf then Ed \#' Ed = (C1\^h1 \* C2\^h2 \* E0 + C1\^h1 \* C2\^h2 \* E2) / \#' (C1\^h1 \* C2\^h2 + C1\^h1 \* C2\^h2) \#' = (E0 + E2) / 2 \#' \#'@export MuSyC_model \<- function( data, group_vars = vars(compound), formula = MuSyC_formula(), prior = MuSyC_prior(), init = MuSyC_init(), combine = FALSE, verbose = FALSE, iter = 8000, cores = 4, stan_model_args = list(verbose = FALSE), control = list( adapt_delta = .99, max_treedepth = 12), model_evaluation_criteria = c("loo", "bayes_R2"), ...) {

if (is.data.frame(well_scores)) { grouped_data \<- well_scores \|\> dplyr::group_by(!!!group_vars) \|\> dplyr::mutate( d1_scale_factor = max(dose1), d2_scale_factor = max(dose2)) \|\> tidyr::nest() \|\> dplyr::ungroup() }

if (verbose) { cat("Fitting MuSyC model\n") }

model \<- brms::brm_multiple( formula = formula, data = grouped_data\$data, family = binomial("identity"), prior = prior, init = init, \# stanvars = c( \# brms::stanvar( \# scode = " real d1_scale_factor = max(dose1));", \# block ="tdata", \# position = "end"), \# brms::stanvar( \# scode = " real d2_scale_factor = max(dose2));", \# block ="tdata", \# position = "end"), \# brms::stanvar( \# scode = " real drug1_IC50 = b_C1 \* d1_scale_factor);", \# block ="genquant", \# position = "end"), \# brms::stanvar( \# scode = " real drug2_IC50 = b_C2 \* d2_scale_factor;", \# block ="genquant", \# position = "end")), combine = FALSE, data2 = NULL, iter = iter, cores = cores, stan_model_args = stan_model_args, control = control, ...)

if (!is.null(model_evaluation_criteria)) { \# evaluate fits model \<- model \|\> purrr::imap(function(model, i) { group_index \<- grouped_data[i, ] \|\> dplyr::select(-data) group_index_label \<- paste0( names(group_index), ":", group_index, collapse = ",") cat("Evaluating model fit for", group_index_label, "...\n", sep = "") model \<- model \|\> brms::add_criterion( criterion = model_evaluation_criteria, model_name = paste0("MuSyC:", group_index_label), reloo = TRUE) model }) } grouped_data \|\> dplyr::mutate( model = model) }
